ORIC Pharmaceuticals develops therapies that target mechanisms of cancer resistance, including innate, acquired, and bypass resistance, to enhance the effectiveness and duration of existing cancer treatments. By focusing on these resistance pathways, ORIC aims to improve clinical outcomes for patients facing therapeutic challenges in oncology.
Funding
$125M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatments often face the challenge of therapeutic resistance, where tumors develop mechanisms to evade the effects of drugs, limiting their long-term efficacy and leading to relapse. These resistance mechanisms can be innate, acquired, or bypass resistance, each presenting unique obstacles to sustained treatment response.
Solution
ORIC Pharmaceuticals is developing therapies specifically designed to overcome cancer resistance mechanisms, aiming to improve the effectiveness and duration of existing cancer treatments. Their approach focuses on addressing innate resistance (unaddressed oncogenic drivers), acquired resistance (induced or enriched oncogenic drivers in response to treatment), and bypass resistance (activation of compensatory signaling pathways). By targeting these resistance pathways, ORIC seeks to enhance the clinical benefit of cancer therapies and improve outcomes for patients facing therapeutic challenges.
Target Audience
The primary target audience includes patients with cancers exhibiting resistance to existing therapies, as well as oncologists and researchers seeking to improve treatment outcomes in challenging oncology cases.
Features
- Focus on innate resistance mechanisms arising from unaddressed oncogenic drivers.
- Development of therapies to combat acquired resistance resulting from treatment-induced oncogenic drivers.
- Targeting bypass resistance through the activation of compensatory signaling pathways.
- Clinical trials currently enrolling for ORIC-114 in EGFR/HER2 mutated cancers.
- Clinical trials currently enrolling for ORIC-944 in prostate cancer in combination with AR inhibitors.